Landscapes / Companies
Pharming Technologies B.V. not checked
FollowEvery new trial, moved date and filing, and a Monday email
Drugs
2
in active trials · 5 in all
Trials
5 active
12 since 2021
Drugs2
| Drug | How it works | Partner | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
Kinase inhibitor |
Approved | 30 Nov 2026soonPhase 3 trial completes | |||
| How it works | Blocks a kinase | ||||
| Next date | 30 Nov 2026 · Phase 3 trial completes | ||||
| Also tested for | APDS, PIDs Linked to PI3K | ||||
| Open drug page | |||||
— |
Abliva AB |
Phase 2 | Oct 2027Phase 2 trial completes | ||
| Next date | Oct 2027 · Phase 2 trial completes | ||||
| Also tested for | Primary Mitochondrial Disease, Mitochondrial Diseases | ||||
| Open drug page | |||||
About
- No active trial
- CDZ173, conestat alfa, rhC1INH
- SEC filings
- None: it does not file with the US SEC
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 Industry-sponsored drug trials since 2021